Bifidobacterium bifidum BB223

High-tech manufacturing process
 

What is Bifidobacterium bifidum?

Bifidobacterium bifidum is one of the most common probiotic bacteria in the human body and the Bifidobacterium species accounts for more than 80% of the microorganisms in the intestine.

Like the other Bifidobacterium species, B. Bifidum is anaerobic and therefore does not need oxygen to survive. Most of the B. Bifidum in our organisms can be found in the large intestine, the lower small intestine, breast milk and in the vagina.

Bifidobacterium bifidum has many health properties and reduces the frequency and risk of acute diarrhoea, as well as infections of other pathogens such as E. coli. And people who suffer from obesity, diabetes and numerous allergies appear to have a lower number of Bifidobacteria in their intestinal tract. For women, B. Bifidum is useful for maintaining the health of the vaginal canal.

Bifidobacterium bifidum attaches itself to the mucous membrane of the gastrointestinal tract, where it helps your body to digest certain sugars. It also supports the immune system and repels pathogens and toxins before they can reach the bloodstream. Recent research even shows that B. Bifidum reduces the incidence of colds and flu.

Bifidobacterium bifidum also helps restore intestinal health in people with gastrointestinal disorders. People suffering from sour dyspepsia, abdominal pain, diarrhoea and constipation have seen a significant improvement in their symptoms after regular consumption of fermented milk containing B. Bifidum. This contributed to an improvement in their mental health, with many reports of less anger and hostility.

B. Bifidum fights candida & yeast overgrowth in our body. Candida infections are often associated with low concentrations of B. Bifidum.

 

More information

Why choosing Bifidobacterium bifidum BB223?

Fermedics’ probiotics are manufactured to the highest standard and based on years of scientific research. Our patented probiotic strains are different from the others since all our probiotics are protected by a patented five-layer microencapsulation technology!

This 5-layer protection also has the following advantages:

  • major logistical advantages
  • probiotic strains also remain more stable in the capsule or sachet
  • no contamination / interaction with the filling system
  • a fluid powder that is easy to encapsulate

In general, only a few % of the probiotics sold can reach the intestines and this is very little. Most of them are dead before they’re consumed and the probiotics that are still alive, are eliminated by more than 60% through the intestinal juices.

 

Tests with probiotics subjected to 5-layer microencapsulation

The 5-layer protection significantly increases the stability and survival of probiotics and has many advantages compared to unprotected probiotics.

The tests clearly show that coated probiotics are resistant to stomach acid, bile salts and other digestive juices, allowing them to reach the intestine intact, which is not the case with unprotected probiotics. Improving the stability and protection against digestive juices of protected probiotics also means that a lower dosage per day is necessary (cost savings) because of the good protection (6 to10 billion bacteria is a good daily dosage).

Stability test shows that coated probiotics remain almost intact (loss of 7 to 8%) after the first 6 months of storage at room temperature, while uncoated probiotics lose nearly 80% of their activity, which is remarkable. Stability test at room temperature for 12 months shows that coated lactic acid bacteria (through patented 5-layer microencapsulation) are much more robust and stable than uncoated bacteria that have already lost much of their activity after 3 months, and after 6 months there is almost no activity, which is absolutely not the case with coated bacteria.

 

Improving storage stability of probiotics

Both uncoated and coated (by patented 5-layer microencapsulation) lactic acid bacteria were stored at 40 °C for four weeks. The result shows that the efficiency of lactic acid bacteria subjected to patented 5-layer microencapsulation is much better (more than 9 log).

 

Properties of Fermedics’ probiotics

More information

Health benefits

  • Reducing allergies
  • Reducing inflammation
  • Combating candida
  • Combating E. coli infections
  • Improving gastrointestinal function
  • Improving mental health
  • Boosting immunity function
  • Promoting mineral absorption
  • Reducing ulcers
  • Treating acute diarrhea

Storage condition

  • Transport is in refrigerated conditions. Therefore, it is preferable that the manufacturer of finished products keeps the raw material in refrigerated state until the beginning of production.
  • Frozen probiotics can easily be stored as a raw material for 2 years without having a significant effect on CFU/g. If probiotics are stored in the refrigerator at 4°C – 8°C, the storage time is also substantially better than at room temperature.
  • After production, probiotics in the package should also preferably be stored in the refrigerator between 4°C – 8 °C, as the result is always better for CFU/g.
  • As soon as the finished products leave the company for distribution to wholesalers and retailers, probiotics can be stored at room temperature (+/- 12 months) if the 25°C is not exceeded. This guarantees the consumer a quality product, even if stored at room temperature.
  • Expiry date: 18 months if the preservation conditions are applied as above.

Technical properties

Fermedics offers you on request all technical data of this ingredient, such as Certificate of Analysis (COA) and price quotation.

MOQ (minimum order quantity) 10 kg

Legislation

Bifidobacterium bifidum belongs to the list of micro-organisms that have obtained Qualified Presumption of Safety (QPS) status, defined by EFSA in Europe (2007) because of their safe use in food (1).

(1) Annex II of Regulation (EU) No 1169/2011

SourceIncubation methodeIdentification of microbePotencyFormRecommended daily dosage
fermented soybean milkdeep-layer liquid state incubation16S rDNA gene sequencing1.0 x 1011 CFU/gpowder6.0 x 109

This probiotic is obtained by a fermentation process, freeze-dried and subjected to a patented five-layer microencapsulation technology to protect and preserve each individual probiotic strain optimally. It is a white to cream-coloured, free-flowing powder with high stability.

Would you like to receive more scientific info about our probiotics?

Yes please

References

  • Ashraf R, Shah NP. Immune system stimulation by probiotic microorganisms. Crit Rev Food Sci Nutr. 2014;54(7):938-56.
  • Depeint F, Tzortzis G, Vulevic J, I’anson K, Gibson GR. Prebiotic evaluation of a novel galactooligosaccharide mixture produced by the enzymatic activity of Bifidobacterium bifidum NCIMB 41171, in healthy humans: a randomized, double-blind, crossover, placebo-controlled intervention study. Am J Clin Nutr. 2008 Mar;87(3):785-91.
  • De Simone C, Ciardi A, Grassi A, Lambert Gardini S, Tzantzoglou S, Trinchieri V, Moretti S, Jirillo E. Effect of Bifidobacterium bifidum and Lactobacillus acidophilus on gut mucosa and peripheral blood B lymphocytes. Immunopharmacol Immunotoxicol. 1992;14(1-2):331-40.
  • De Vrese M, Winkler P, Rautenberg P, Harder T, Noah C, Laue C, Ott S, Hampe J, Schreiber S, Heller K, Schrezenmeir J. Effect of Lactobacillus gasseri PA 16/8, Bifidobacterium longum SP 07/3, B. bifidum MF 20/5 on common cold episodes: a double blind, randomized, controlled trial. Clin Nutr. 2005 Aug;24(4):481-91.
  • Langkamp-Henken, Rowe CC, Ford Al, et al. Bifidobacterium bifidum R0071 results in a greater proportion of healthy days and a lower percentage of academically stressed students reporting a day of cold/flu: a randomised, double-blind, placebo-controlled study. Br J Nutr. 2015 Feb 14;113(3):426-34
  • LeBlanc JG, Milani C, de Giori GS, et al. Bacteria as vitamin suppliers to their host: a gut microbiota perspective. Curr Opin Biotechnol. 2013 Apr;24(2):160-8.
  • Mary Hickson. Probiotics in the prevention of antibiotic-associated diarrhoea and Clostridium difficile infection. Therap Adv Gastroenterol. 2011 May; 4(3): 185-197.
  • Saavedra JM, Bauman NA, Oung I, Perman JA, Yolken RH. Feeding of Bifidobacterium bifidum and Streptococcus thermophilus to infants in hospital for prevention of diarrhoea and shedding of rotavirus. Lancet. 1994 Oct 15;344(8929):1046-9.